Opdivo trial stopped early after showing survival advantage in lung cancer

US pharma major Bristol-Myers Squibb (NYSE: BMY) has announced that a Phase III study evaluating Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) was stopped early because it met its endpoint.

The independent Data Monitoring Committee (DMC) concluded that the study demonstrated superior overall survival in patients receiving Opdivo compared to the control arm.

Michael Giordano, senior vice president, head of development, oncology, B-MS, said: “The results of CheckMate -057 mark the second time Opdivo has demonstrated a survival advantage in lung cancer. Through our Opdivo clinical development program, we seek to bring the potential for long-term survival to a broad range of patients, across lines of therapy and stages of disease.”